Benedict B. Benigno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Benedict B. Benigno has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- John F. McDonald
Integrated Cancer Research Center, School of Biological Sciences, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA
4 shared publications - DeEtte Walker
Integrated Cancer Research Center, School of Biology, and Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, 315 Ferst Dr, Atlanta, GA 30332, USA
2 shared publications - Lilya V. Matyunina
School of Biological Sciences and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA, 30332, USA
2 shared publications - Carol Aghajanian
Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
1 shared publication - Carolyn Y. Muller
NCORP, University of New Mexico Cancer Center, Albuquerque, NM, United States of America
1 shared publication - Christopher G Hill
Integrated Cancer Research Center, School of Biology, and Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, 315 Ferst Dr, Atlanta, GA 30332, USA
1 shared publication
Latest Publications
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 393-399
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 393-399
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
- 30 October 2018
- Published by Springer Nature
- p. 307-313
Ovarian Cancer in Pregnancy
- 1 July 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 134 (1) , 96-103
Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells
- 1 July 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 134 (1) , 96-103
Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells
- Open Access
- 25 March 2014
- Published by Springer Nature in BMC Systems Biology
- Vol. 8 (1) , 36
Transcriptional override: a regulatory network model of indirect responses to modulations in microRNA expression
Documented changes in levels of microRNAs (miRNA) in a variety of diseases including cancer are leading to their development as early indicators of disease, and as a potential new class of therapeutic agents. A significant hurdle to the rational application of miRNAs as therapeutics is our current inability to reliably predict the range of molecular and cellular consequences of perturbations in the levels of specific miRNAs on targeted cells. While the direct gene (mRNA) targets of individual miRNAs can be computationally predicted with reasonable degrees of accuracy, reliable predictions of the indirect molecular effects of perturbations in miRNA levels remain a major challenge in molecular systems biology.
- 25 March 2014
- Published by Springer Nature in BMC Systems Biology
- Vol. 8 (1) , 36
Open AccessTranscriptional override: a regulatory network model of indirect responses to modulations in microRNA expression
Documented changes in levels of microRNAs (miRNA) in a variety of diseases including cancer are leading to their development as early indicators of disease, and as a potential new class of therapeutic agents. A significant hurdle to the rational application of miRNAs as therapeutics is our current inability to reliably predict the range of molecular and cellular consequences of perturbations in the levels of specific miRNAs on targeted cells. While the direct gene (mRNA) targets of individual miRNAs can be computationally predicted with reasonable degrees of accuracy, reliable predictions of the indirect molecular effects of perturbations in miRNA levels remain a major challenge in molecular systems biology.
- 1 September 2013
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 23 (7) , 1331-1333
High-Dose Chemotherapy With Autologous Stem Cell Support as Salvage Therapy in Recurrent Gestational Trophoblastic Disease
- 1 September 2013
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 23 (7) , 1331-1333
High-Dose Chemotherapy With Autologous Stem Cell Support as Salvage Therapy in Recurrent Gestational Trophoblastic Disease
- Open Access
- 10 July 2013
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 6 (1) , 49
Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis
Background: While metastasis ranks among the most lethal of all cancer-associated processes, on the molecular level, it remains one of the least well understood. One model that has gained credibility in recent years is that metastasizing cells at least partially recapitulate the developmental process of epithelial-to-mesenchymal transition (EMT) in their transit from primary to metastatic sites. While experimentally supported by cell culture and animal model studies, the lack of unambiguous confirmatory evidence in cancer patients has led to persistent challenges to the model’s relevance in humans. Methods: Gene expression profiling (Affymetrix, U133) was carried out on 14 matched sets of primary (ovary) and metastatic (omentum) ovarian cancer (serous adenocarcinoma) patient samples. Hierarchical clustering and functional pathway algorithms were used in the data analysis. Results: While histological examination reveled no morphological distinction between the matched sets of primary and metastatic samples, gene expression profiling clearly distinguished two classes of metastatic samples. One class displayed expression patterns statistically indistinguishable from primary samples isolated from the same patients while a second class displayed expression patterns significantly different from primary samples. Further analyses focusing on genes previously associated with EMT clearly distinguished the primary from metastatic samples in all but one patient. Conclusion: Our results are consistent with a role of EMT in most if not all ovarian cancer metastases and demonstrate that identical morphologies between primary and metastatic cancer samples is insufficient evidence to negate a role of EMT in the metastatic process.
- 10 July 2013
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 6 (1) , 49
Open AccessMolecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis
Background: While metastasis ranks among the most lethal of all cancer-associated processes, on the molecular level, it remains one of the least well understood. One model that has gained credibility in recent years is that metastasizing cells at least partially recapitulate the developmental process of epithelial-to-mesenchymal transition (EMT) in their transit from primary to metastatic sites. While experimentally supported by cell culture and animal model studies, the lack of unambiguous confirmatory evidence in cancer patients has led to persistent challenges to the model’s relevance in humans. Methods: Gene expression profiling (Affymetrix, U133) was carried out on 14 matched sets of primary (ovary) and metastatic (omentum) ovarian cancer (serous adenocarcinoma) patient samples. Hierarchical clustering and functional pathway algorithms were used in the data analysis. Results: While histological examination reveled no morphological distinction between the matched sets of primary and metastatic samples, gene expression profiling clearly distinguished two classes of metastatic samples. One class displayed expression patterns statistically indistinguishable from primary samples isolated from the same patients while a second class displayed expression patterns significantly different from primary samples. Further analyses focusing on genes previously associated with EMT clearly distinguished the primary from metastatic samples in all but one patient. Conclusion: Our results are consistent with a role of EMT in most if not all ovarian cancer metastases and demonstrate that identical morphologies between primary and metastatic cancer samples is insufficient evidence to negate a role of EMT in the metastatic process.
- 20 September 2010
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 4 (8-9) , 752
Identification of candidate biomarkers with cancer‐specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis
- 20 September 2010
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 4 (8-9) , 752
Identification of candidate biomarkers with cancer‐specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis